A patient with confirmed severe thrombocytopenia and suspected aplastic anemia is being considered for corticosteroid therapy. Which of the following nursing interventions is most important in managing this patient’s care?

C) Assess for signs of gastrointestinal bleeding and report any abnormalities immediately.

A) Monitor blood pressure closely and adjust antihypertensive medications as needed.

B) Educate the patient on the signs of infection due to immunosuppression from corticosteroids.

C) Assess for signs of gastrointestinal bleeding and report any abnormalities immediately.

D) Schedule regular physical therapy sessions to maintain muscle strength during treatment.

A patient with severe thrombocytopenia and a recent bone marrow biopsy indicating hypocellular marrow with decreased megakaryocytes is being considered for corticosteroid therapy. Which nursing intervention is a priority to prevent complications associated with the proposed treatment?

D) Scheduling regular blood glucose monitoring to detect steroid-induced hyperglycemia

A) Administering platelet transfusions to maintain platelet count above 100,000/µL

B) Monitoring blood pressure closely to manage potential exacerbation of hypertension

C) Providing patient education on the importance of avoiding injury and bleeding risks

D) Scheduling regular blood glucose monitoring to detect steroid-induced hyperglycemia

A patient with severe thrombocytopenia and diabetes is on corticosteroid therapy and exhibits early signs of steroid-induced hyperglycemia. Her blood glucose levels are now consistently elevated despite oral hypoglycemic agents. What should be the nurse's primary concern in managing this patient's care?

B) Initiating a sliding scale insulin regimen to better control blood glucose levels

A) Adjusting the corticosteroid dosage to reduce hyperglycemia risk

B) Initiating a sliding scale insulin regimen to better control blood glucose levels

C) Monitoring for signs of infection due to immunosuppression

D) Addressing the patient's fatigue and shortness of breath with supplemental oxygen

A patient with severe thrombocytopenia is being treated with corticosteroids. She has developed steroid-induced hyperglycemia and her blood glucose levels have increased despite adherence to oral hypoglycemic agents. The healthcare team has introduced a sliding scale insulin regimen. The patient also shows signs of fatigue and mild shortness of breath. Her hemoglobin level has decreased, indicating possible bone marrow suppression. Which nursing intervention is the most appropriate to prioritize at this time?

A) Educate the patient about the importance of consistent blood glucose monitoring and insulin administration.

B) Discuss with the healthcare provider the need for a potential blood transfusion due to low hemoglobin levels.

C) Coordinate a consult with a cardiologist to evaluate for cardiac complications and conduct an echocardiogram.

D) Monitor the patient for signs of infection and bleeding due to the risk of further bone marrow suppression.

A patient with diabetes and a history of corticosteroid use presents with increasing fatigue and mild shortness of breath. An echocardiogram shows mild left ventricular hypertrophy, and laboratory tests reveal slightly elevated BUN and creatinine levels. Which nursing intervention should be prioritized to address her current condition?

C) Monitor blood glucose levels closely and adjust insulin as needed.

A) Administer supplemental oxygen to improve tissue perfusion.

B) Educate the patient on dietary modifications to support renal function.

C) Monitor blood glucose levels closely and adjust insulin as needed.

D) Encourage increased fluid intake to enhance renal clearance.

A patient with a history of diabetes and recent corticosteroid therapy presents with increasing fatigue and mild shortness of breath. An echocardiogram shows mild left ventricular hypertrophy without significant valve issues, and lab results indicate slight renal function decline. Which nursing intervention is the most appropriate to prioritize at this time?

B) Monitor blood glucose levels closely to ensure tight glycemic control and prevent additional renal strain.

A) Educate the patient on the importance of fluid restriction to prevent further renal impairment.

B) Monitor blood glucose levels closely to ensure tight glycemic control and prevent additional renal strain.

C) Advise the patient to increase dietary sodium to compensate for potential steroid-induced hyponatremia.

D) Encourage increased physical activity to improve cardiovascular function and reduce fatigue.

A patient with thrombocytopenia has reported increased bruising and petechiae, with a recent decline in platelet count despite treatment. The patient also exhibits mild tachycardia and increased fatigue. Considering these clinical findings, what is the nurse's priority intervention?

C) Educate the patient on safety measures to prevent bleeding.

A) Administer supplemental oxygen to address potential hypoxia.

B) Prepare the patient for a bone marrow biopsy as ordered.

C) Educate the patient on safety measures to prevent bleeding.

D) Monitor blood glucose levels closely due to corticosteroid adjustment.

A patient with thrombocytopenia has experienced a decline in platelet count and reports increased bruising and petechiae. The healthcare team has decided to increase the corticosteroid dose. What is the most appropriate nursing intervention to prioritize in this scenario?

C) Assess the patient's blood glucose levels more frequently.

A) Monitor the patient for signs of infection due to immunosuppression.

B) Educate the patient on the importance of avoiding contact sports.

C) Assess the patient's blood glucose levels more frequently.

D) Encourage the patient to increase fluid intake to prevent dehydration.

A patient with severe thrombocytopenia and suspected gastrointestinal bleeding is receiving corticosteroids and IVIG therapy. Which of the following nursing interventions is most critical to implement to prevent further complications in this patient?

C) Regularly assess vital signs and observe for changes in blood pressure and heart rate.

A) Monitor for signs of hyperglycemia and adjust insulin as needed.

B) Administer antiemetic medication to prevent nausea and vomiting.

C) Regularly assess vital signs and observe for changes in blood pressure and heart rate.

D) Encourage the patient to increase fluid intake to maintain hydration.

A patient with a declining platelet count of 40,000/µL and new onset gastrointestinal bleeding is being treated with corticosteroids and IVIG. As the nurse, what is the priority intervention to prevent further complications?

A) Monitor the patient for signs of hypovolemic shock and prepare for possible blood transfusion.

B) Educate the patient about dietary restrictions to minimize gastrointestinal irritation.

C) Administer prescribed antacids to prevent steroid-induced gastric ulcers.

D) Encourage increased fluid intake to support renal function.

thrombocytopenia - Nursing Case Study

Pathophysiology

• Primary mechanism: Decreased platelet production - This occurs when the bone marrow fails to produce enough platelets due to conditions like aplastic anemia, leukemia, or exposure to certain drugs and toxins, leading to a reduced ability to form blood clots and increased bleeding risk.

• Secondary mechanism: Increased platelet destruction - Autoimmune disorders such as immune thrombocytopenic purpura (ITP) trigger the immune system to mistakenly destroy platelets, resulting in lower platelet counts and impaired clotting function.

• Key complication: Risk of bleeding - With fewer platelets available, patients are prone to bleeding complications ranging from minor bruising to severe hemorrhages, necessitating careful monitoring and management to prevent serious outcomes.

Patient Profile

Demographics:

42-year-old female, nurse

History:

• Key past medical history: Hypertension, Type 2 Diabetes, history of anemia

• Current medications: Lisinopril, Metformin, Iron supplements

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increased bruising and fatigue

• Key symptoms: Petechiae on lower extremities, bleeding gums, mild dizziness

• Vital signs: Blood pressure 150/95 mmHg, heart rate 102 bpm, respiratory rate 20 breaths per minute, temperature 98.6°F

Section 1

As the clinical team continues to evaluate the patient, new diagnostic results provide further insight into her condition. A complete blood count reveals a platelet count of 25,000/µL, significantly below the normal range of 150,000 to 450,000/µL, confirming severe thrombocytopenia. Additionally, the peripheral blood smear shows large, immature platelets, which suggests the presence of bone marrow stress. Further laboratory tests, including a bone marrow biopsy, are conducted to assess the potential causes of reduced platelet production. The biopsy indicates hypocellular marrow with decreased megakaryocytes, pointing towards possible aplastic anemia rather than leukemia, given the patient's stable white blood cell and red blood cell counts.

These findings prompt the healthcare team to adjust their management strategy. Given the underlying risk of bleeding and the potential autoimmune mechanism, the team considers initiating corticosteroid therapy to suppress any immune-mediated platelet destruction. However, they must carefully balance this intervention with the patient's existing comorbid conditions, particularly her hypertension and diabetes, which could be exacerbated by steroid use. The patient's recent bruising and gum bleeding necessitate close monitoring for any signs of worsening, such as gastrointestinal bleeding or severe hemorrhagic events, which would require immediate medical intervention.

As the patient's care progresses, the team must remain vigilant for new complications that could arise from both the underlying thrombocytopenia and the treatment itself. The potential for infections due to immunosuppression, or the development of steroid-induced hyperglycemia, are concerns that require proactive management. Regular follow-up with complete blood counts and periodic reassessment of the patient's clinical status will be essential to ensure timely adjustments to her treatment plan and to mitigate the risk of serious adverse events.

Section 2

As the clinical team continues to manage the patient's severe thrombocytopenia, they closely monitor her response to the initiated corticosteroid therapy. Within a week, the patient begins to exhibit early signs of steroid-induced hyperglycemia, a common complication given her comorbid diabetes. Her blood glucose levels, previously managed with oral hypoglycemic agents, now consistently range between 180 to 220 mg/dL, despite adherence to her medication regimen. This necessitates an adjustment in her diabetes management plan, which includes the introduction of sliding scale insulin to better control her blood sugar levels.

Concurrently, the team observes a slight improvement in her platelet count, which has risen to 35,000/µL, indicating a positive response to the corticosteroids in terms of reducing immune-mediated destruction. However, this improvement is tempered by the emergence of new complications. The patient begins to experience increasing fatigue and mild shortness of breath, raising concerns about potential anemia or other cardiovascular strain. A repeat complete blood count reveals a hemoglobin level of 9.2 g/dL, a drop from her baseline, suggesting that her bone marrow suppression may be more extensive than initially thought.

The team faces a critical juncture in her care, requiring careful clinical reasoning to balance the benefits of ongoing immunosuppression with the risks of further complications. They consider additional diagnostic investigations, such as an echocardiogram to rule out cardiac involvement or a more comprehensive metabolic panel to assess renal function, given her risk factors. The decision-making process must weigh the potential need for transfusion support against the risks of alloimmunization and further complicating her already delicate condition. These developments necessitate a multidisciplinary approach, engaging endocrinologists, hematologists, and cardiologists to refine her treatment plan and prevent deterioration.

Section 3

As the clinical team continues to navigate the complexities of the patient's condition, they decide to prioritize the investigation of her increasing fatigue and mild shortness of breath. An echocardiogram is conducted, revealing mild left ventricular hypertrophy but no significant valvular abnormalities or signs of heart failure. This finding suggests that her cardiovascular symptoms may not be directly linked to cardiac dysfunction, but rather a reflection of her anemic status and potential impacts on oxygen delivery and tissue perfusion.

Simultaneously, a comprehensive metabolic panel is performed to assess her renal function and electrolyte status. The results show a slightly elevated blood urea nitrogen (BUN) of 28 mg/dL and a creatinine level of 1.3 mg/dL, indicating a mild decline in renal function from her baseline. Electrolyte levels remain within normal limits, but the team acknowledges the need to monitor her renal status closely, given the interplay between her diabetes management and corticosteroid use.

Recognizing the multifaceted nature of her condition, the team decides to enhance their multidisciplinary approach. A consultation with a nephrologist is arranged to evaluate the impact of her current treatment on renal health and explore possible nephroprotective strategies. Meanwhile, the endocrinologist suggests further adjustments to her insulin regimen, aiming for tighter glycemic control to mitigate the risk of exacerbating renal strain. The team carefully balances these interventions with ongoing support from the hematologist, who recommends continuing corticosteroids at a modified dose to sustain platelet improvement while minimizing adverse effects. This collaborative strategy aims to stabilize her condition, allowing for a reassessment of her treatment plan in response to evolving clinical needs.

Section 4

As the multidisciplinary team continues to address the complexities of the patient's thrombocytopenia and associated conditions, they observe a notable change in her status. Over the next few days, the patient reports increased bruising and petechiae, particularly on her extremities. Her platelet count, previously stabilized around 80,000/µL with corticosteroid therapy, has now dropped to 50,000/µL. This unexpected decline prompts a reassessment of her treatment plan. The hematologist decides to conduct a bone marrow biopsy to investigate potential underlying causes such as bone marrow suppression or an evolving hematologic disorder. Meanwhile, her hemoglobin level remains stable at 9.5 g/dL, and her white blood cell count is within normal limits, suggesting that the drop in platelet count is an isolated hematologic issue rather than part of a broader cytopenia.

In light of these developments, the team also notes a slight increase in her fatigue and shortness of breath, correlating with a new mild tachycardia—her resting heart rate has risen to 98 beats per minute, up from her baseline of 82. Blood pressure remains within her typical range at 130/85 mmHg, and oxygen saturation is stable at 95% on room air. These symptoms, coupled with her lab results, lead the team to suspect that the decrease in platelet count and the mild anemia are contributing to her symptoms. The nephrologist reassesses her renal function, which remains stable with a BUN of 30 mg/dL and creatinine of 1.4 mg/dL, suggesting that while her renal function requires ongoing surveillance, it is not the primary driver of her current clinical changes.

To address the new complications, the hematologist suggests a cautious increase in the corticosteroid dose to prevent further platelet decline, while the endocrinologist emphasizes the importance of maintaining optimal blood glucose levels to prevent exacerbation of her renal condition. The team also considers the potential need for intravenous immunoglobulin (IVIG) therapy if her platelet count continues to decrease. These decisions underscore the need for continuous monitoring and adjustment of her treatment plan, balancing the risks of thrombocytopenia and its complications with the side effects of intensified therapy. The team schedules a follow-up in 48 hours to re-evaluate her clinical status and adjust interventions accordingly, ensuring that they remain responsive to her evolving needs.

Section 5

As the multidisciplinary team reconvenes for the 48-hour follow-up, they observe a notable change in the patient's status, warranting immediate attention. The patient's platelet count has further declined to 40,000/µL despite the cautious increase in corticosteroid therapy. This alarming drop is accompanied by new onset gastrointestinal symptoms, including mild epigastric pain and two episodes of hematochezia, raising concerns about possible gastrointestinal bleeding secondary to severe thrombocytopenia. Vital signs reveal a heart rate that has increased to 105 beats per minute, and her blood pressure has slightly decreased to 120/80 mmHg, though her oxygen saturation remains at 94% on room air.

These developments prompt a focused reassessment of her current condition. The hematologist quickly orders a stat coagulation profile, revealing a prolonged prothrombin time (PT) of 15 seconds, suggesting a potential coagulopathy. The team considers this finding in conjunction with her low platelet count and new gastrointestinal symptoms, hypothesizing that the patient may be experiencing a consumptive coagulopathy, possibly related to an undiagnosed evolving hematologic disorder. The nephrologist concurs that although the renal function remains stable, the added stress of gastrointestinal bleeding and increased corticosteroid therapy could threaten renal safety over time.

Recognizing the urgency, the team escalates the patient's care plan. They initiate intravenous immunoglobulin (IVIG) therapy to stabilize her platelet count and mitigate bleeding risks, while also arranging for upper and lower gastrointestinal endoscopy to identify and address the source of the bleeding. The endocrinologist continues to monitor her blood glucose levels closely, adjusting her insulin regimen to counteract any hyperglycemic effects from the steroids. The team schedules another reassessment in the next 24 hours, highlighting the need for vigilant monitoring and rapid intervention to prevent further complications and stabilize the patient's condition.